| [1] |
Sung H, Ferlay J, Siegel RL, et al.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J ClinCA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.21660 |
| [2] |
Furuya-Kanamori L, Bell KJL, Clark J, et al.
Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis[J]. J Clin OncolJ Clin Oncol, 2016, 34(30): 3672-3679.
doi: 10.1200/JCO.2016.67.7419 |
| [3] |
McGuire S.
World cancer report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015[J]. Adv NutrAdv Nutr, 2016, 7(2): 418-419.
doi: 10.3945/an.116.012211 |
| [4] |
Sipos JA, Mazzaferri EL.
Thyroid cancer epidemiology and prognostic variables[J]. Clin Oncol (R Coll Radiol)Clin Oncol (R Coll Radiol), 2010, 22(6): 395-404.
doi: 10.1016/j.clon.2010.05.004 |
| [5] |
Haugen BR, Alexander EK, Bible KC, et al.
2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. ThyroidThyroid, 2016, 26(1): 1-133.
doi: 10.1089/thy.2015.0020 |
| [6] |
林岩松.
分化型甲状腺癌的碘-131治疗现状和进展[J]. 中华耳鼻咽喉头颈外科杂志中华耳鼻咽喉头颈外科杂志, 2019, 54(1): 62-68.
doi: 10.3760/cma.j.issn.1673-0860.2019.01.016 Lin YS. Postoperative treatment of differentiated thyroid carcinoma with radioiodine-131[J]. Chin J Otorhinolaryngol Head Neck SurgChin J Otorhinolaryngol Head Neck Surg, 2019, 54(1): 62-68. doi: 10.3760/cma.j.issn.1673-0860.2019.01.016 |
| [7] |
Verburg FA, Flux G, Giovanella L, et al.
Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2020, 47(1): 78-83.
doi: 10.1007/s00259-019-04479-1 |
| [8] |
Tuttle RM, Ahuja S, Avram AM, et al.
Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association[J]. ThyroidThyroid, 2019, 29(4): 461-470.
doi: 10.1089/thy.2018.0597 |
| [9] |
Hackshaw A, Harmer C, Mallick U, et al.
131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2007, 92(1): 28-38.
doi: 10.1210/jc.2006-1345 |
| [10] |
姜玉艳, 谭建, 张桂芝, 等.
1.1GBq和3.7GBq 131I对中低危分化型甲状腺癌的清甲疗效比较[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2019, 39(9): 526-531.
doi: 10.3760/cma.j.issn.2095-2848.2019.09.004 Jiang YY, Tan J, Zhang GZ, et al. Comparison between ablation efficacy of 1.1 GBq and 3.7 GBq 131I for low- and intermediate-risk differentiated thyroid carcinoma[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2019, 39(9): 526-531. doi: 10.3760/cma.j.issn.2095-2848.2019.09.004 |
| [11] |
瞿源, 黄蕤, 董萍, 等.
低剂量和高剂量131I治疗中低危分化型甲状腺癌的随机对照研究[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2016, 36(5): 384-388.
doi: 10.3760/cma.j.issn.2095-2848.2016.05.002 Qu Y, Huang R, Dong P, et al. Low-dose and high-dose 131I therapy for low and intermediate risk differentiated thyroid cancer: a randomized controlled clinical study[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2016, 36(5): 384-388. doi: 10.3760/cma.j.issn.2095-2848.2016.05.002 |
| [12] |
刘娇, 程兵, 常伟, 等.
非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J]. 国际放射医学核医学杂志国际放射医学核医学杂志, 2016, 40(6): 419-423.
doi: 10.3760/cma.j.issn.1673-4114.2016.06.004 Liu J, Cheng B, Chang W, et al. Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2016, 40(6): 419-423. doi: 10.3760/cma.j.issn.1673-4114.2016.06.004 |
| [13] |
张桂芝, 谭建, 刘雪辉, 等.
131I治疗分化型甲状腺癌术后患者疗效影响因素研究[J]. 中华核医学杂志中华核医学杂志, 2010, 30(4): 259-263.
doi: 10.3760/cma.j.issn.0253-9780.2010.04.011 Zhang GZ, Tan J, Liu XH, et al. Influential factors on the effectiveness of 131I treatment on post-surgical differentiated thyroid cancer patients[J]. Chin J Nucl MedChin J Nucl Med, 2010, 30(4): 259-263. doi: 10.3760/cma.j.issn.0253-9780.2010.04.011 |
| [14] |
Park HJ, Jeong GC, Kwon SY, et al.
Stimulated serum thyroglobulin level at the time of first dose of radioactive iodine therapy is the most predictive factor for therapeutic failure in patients with papillary thyroid carcinoma[J]. Nucl Med Mol ImagingNucl Med Mol Imaging, 2014, 48(4): 255-261.
doi: 10.1007/s13139-014-0282-4 |
| [15] |
王月祺, 黄蕤, 李林.
分化型甲状腺癌术后131I治疗及诊断性显像前提高TSH水平的方案及其影响[J]. 国际放射医学核医学杂志国际放射医学核医学杂志, 2020, 44(1): 59-64.
doi: 10.3760/cma.j.issn.1673-4114.2020.01.012 Wang YQ, Huang R, Li L. Methods for improving TSH level and their effect in postoperative patients with differentiated thyroid cancer[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2020, 44(1): 59-64. doi: 10.3760/cma.j.issn.1673-4114.2020.01.012 |
| [16] |
刘晔, 晋建华, 刘建中, 等.
放射性131Ⅰ去除分化型甲状腺癌术后残留甲状腺组织的疗效与影响因素分析[J]. 中国药物与临床中国药物与临床, 2013, 13(5): 556-558.
doi: 10.11655/zgywylc2013.05.003 Liu Y, Jin JH, Liu JZ, et al. Efficacy and influencing factors of radioactive 131I for elimination of thyroid remnants following differentiated thyroid carcinoma resection[J]. Chin Remed ClinChin Remed Clin, 2013, 13(5): 556-558. doi: 10.11655/zgywylc2013.05.003 |